Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01745458 | SB-659032 Platelet Aggregation Study | PHASE1 | COMPLETED | 26 | — | — | Jul 1, 2005 | Dec 1, 2005 | Dec 10, 2012 | 1 | Australia |
| NCT01750827 | A Study to Assess the Effect of SB 659032 on Platelet Function | PHASE1 | COMPLETED | 14 | — | — | Sep 1, 2004 | Nov 1, 2004 | Dec 17, 2012 | 1 | United States |
Percent maximum platelet aggregation following ADP- and collagen-induced aggregation
Urinary 11-dehydrothromboxane B2 and blood CD62 concentrations
| Arm | Type | Description |
|---|---|---|
| SB-659032 | EXPERIMENTAL | 250 mg non-enteric coated SB-659032 |
| Placebo | PLACEBO_COMPARATOR | matched placebo QD for 14 days |
| Name | Type | Description |
|---|---|---|
| SB-659032 | DRUG | - |
| Placebo | DRUG | Matched placebo |
| SB659032 | DRUG | single dose |
Inclusion Criteria: * Healthy adult males between 18 and 55 years of age, inclusive * Body weight greater than 50 kg (110 pounds) and body mass index (BMI) between 19 and 32 where: BMI = weight in kg/(height in meters)2 * A signed and dated written informed consent prior to admission to the study *...